BCB 002Alternative Names: BCB-002
Latest Information Update: 08 Jul 2016
At a glance
- Originator Boryung Pharmaceutical
- Class Antineoplastics; Gene therapies
- Mechanism of Action Gene transference
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Liver cancer
Most Recent Events
- 06 May 2016 Phase-I clinical trials in Liver cancer in South Korea (unspecified route)